Kiniksa stock rocketed 20% after first-quarter results on April 29. The biotech stock then broke out of a cup base with a buy point of 28.15 on May 5. IBD MarketSurge shows that shares traded tightly ...

Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.

Leerink Partners analyst David Risinger has maintained their bullish stance on REGN stock, giving a Buy rating on November 3. David Risinger provided a Buy rating for Regeneron’s stock primarily ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...

Regeneron (REGN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives ...

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its COVID-19 antibody ...

This 120% rise for Regeneron stock since late 2019 can primarily be attributed to 1. the company’s P/S ratio rising 50% to 12.6x revenues vs. 8.4x in 2019, 2.

Regeneron Pharmaceuticals’ Operating Income over the previous four quarters was $3.8 Billion, reflecting a high Operating Margin of 27.2% compared to 13.2% for the S&P 500; Regeneron ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its covid antibody cocktail ...

Regeneron Pharmaceuticals (REGN-19.09%) has made for a fantastic growth story over the years. From just over $2 billion in revenue in 2013, the company's top line rose to more than $12 billion ...

Morgan Stanley analyst Terence Flynn has maintained their bullish stance on REGN stock, giving a Buy rating on June 27. Terence Flynn has given ...